OPK - OPKO Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.8500
-0.0100 (-0.35%)
As of 9:45AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.8600
Open2.8400
Bid2.80 x 2900
Ask2.86 x 1200
Day's Range2.8400 - 2.8700
52 Week Range2.3400 - 6.4000
Volume285,157
Avg. Volume5,280,219
Market Cap1.671B
Beta (3Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about OPKO Health Inc.

    OPKO Health Inc NASDAQ/NGS:OPKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for OPK with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 6. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding OPK totaled $7.59 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Glu Mobile, Opko Health, and Church & Dwight Slumped Today
    Motley Fool14 days ago

    Why Glu Mobile, Opko Health, and Church & Dwight Slumped Today

    Despite a solid upward move for the stock market, these three lagged behind.

  • Why Opko Health Is Tanking Today
    Motley Fool14 days ago

    Why Opko Health Is Tanking Today

    A convertible senior note offering and related issuing of new shares caused the healthcare stock to plunge.

  • GlobeNewswire14 days ago

    OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes

    OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”). The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears at a rate of 4.50% per annum, and will mature on February 15, 2025, unless earlier repurchased, redeemed or converted. The Notes will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.

  • Benzinga14 days ago

    The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...

  • PR Newswire14 days ago

    Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm

    SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join ...

  • GlobeNewswire15 days ago

    OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes

    OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”) in an underwritten public offering. The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears and will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.

  • Opko gets FDA OK for fingerstick test, seeks reversal on non-coverage ruling
    American City Business Journals18 days ago

    Opko gets FDA OK for fingerstick test, seeks reversal on non-coverage ruling

    The medical test and medication company is betting on the future of its 4Kscore diagnostic test, but has hit a roadblock.

  • GlobeNewswire18 days ago

    OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer

    MIAMI, Feb. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total.

  • GlobeNewswire18 days ago

    OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator

    OPKO Health, Inc. (OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM). OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass.

  • GlobeNewswire19 days ago

    Future Non-Coverage Determination for 4Kscore Test Posted by Novitas

    OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test® to be effective March 20, 2019. The notice released by Novitas today does not appear to be different from the draft local coverage determination released by Novitas on May 18, 2018. OPKO is evaluating options to appeal the decision and undertake other steps with the U.S. Centers for Medicare & Medicaid Services (CMS) in an effort to have this determination rescinded or reversed.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: OPKO Health and Endo International

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...

  • GlobeNewswire22 days ago

    BioReference Laboratories Supports Federal Employees Amidst Government Shutdown

    BioReference Laboratories Inc., an OPKO Health Company (OPK), today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position that federal government employees have faced throughout the shutdown,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. BioReference and its divisions, GenPath Diagnostics and GeneDx, developed a program to defer laboratory payments for 30 days to furloughed federal government employees.

  • Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now
    Zacks28 days ago

    Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now

    Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.

  • Varian Medical's (VAR) ProBeam Compact Picked by Biopolis
    Zacks28 days ago

    Varian Medical's (VAR) ProBeam Compact Picked by Biopolis

    The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.

  • GuruFocus.com29 days ago

    Weekly CEO Buys Highlight

    Insiders invest in Valvoline, OPKO Health and American Finance Trust

  • Insiders Roundup: Stryker Corp, OPKO Health
    GuruFocus.comlast month

    Insiders Roundup: Stryker Corp, OPKO Health

    Largest insider trades of the week

  • Cerner Picked by Remi Vista for Behavioral Health Technology
    Zackslast month

    Cerner Picked by Remi Vista for Behavioral Health Technology

    Apart from Cerner Integrated, Cerner's (CERN) revenue cycle solutions will help Remi Vista's financial operations.

  • Here's Why Investors Should Retain athenahealth (ATHN) Stock
    Zackslast month

    Here's Why Investors Should Retain athenahealth (ATHN) Stock

    athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.

  • Allscripts Selected by Premier for Connected Health Platform
    Zackslast month

    Allscripts Selected by Premier for Connected Health Platform

    Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.

  • Here's Why You Should Invest in OPKO Health (OPK) Right Now
    Zackslast month

    Here's Why You Should Invest in OPKO Health (OPK) Right Now

    OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.

  • Here's Why Investors Should Hold Patterson Companies Stock
    Zackslast month

    Here's Why Investors Should Hold Patterson Companies Stock

    Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.